comprehensive -WSS

comprehensive

author：entertainment 2025-09-07 06:41:13 - browse：29675

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： As obesity drug market grows, telehealth companies court payers

focus

WSS

As obesity drug market grows, telehealth companies court payers

Senate panel eyes new effort on drug shortages

AI can decode, harness the power of the humane immune system

How the drug

Was Amgen transparent enough on FDA's concern on cancer drug?

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Wikipedia

comprehensive

focus

Activists slam private health insurers over coverage restrictions

Study: Spinal cord stimulation helps patients with paralysis walk again

What does generative AI mean for health care? We asked experts

Vivek Ramaswamy made waves in the debate, much as in biotech

The cancer drug shortage isn’t new — and neither are the solutions

Roche's accidental data boosts hopes for anti

Medical records are filled with copy

Abortion policy in the spotlight at Republican debate

Heart attack and stroke risk calculators need revising

Trans patients at the end of life deserve respect and dignity

focus

Meadows told special counsel he could not recall Trump ever declassifying Mar

AI can decode, harness the power of the humane immune system

FDA authorizes Novavax’s updated Covid

What past blockbusters can tell us about future of Wegovy and other weight loss medicines

FDA panel signals lack of confidence in Amgen cancer drug data

A virus, fished out of a lake, may have saved a man’s life

focus

focus

knowledge

knowledge